1. The various angiotensin-converting enzyme inhibitors have structural differences which affect their affinities for the catalytic sites on converting enzyme. We postulated that such differences might result in differences in renoprotective efficacy. We investigated this in the diabetic spontaneous hypertensive rat. We also investigated whether these differences might reflect variations in glo...

BACKGROUND AND PURPOSE Although the efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in reducing future vascular events for patients with coronary heart disease is established, less is known about the precise benefit of these agents among patients with stroke. We evaluated whether use of angiotensin-converting enzyme inhibitors or angiotensin receptor block...

Angioedema is a potentially life-threatening adverse effect of angiotensin-converting enzyme inhibitors. Bradykinin and substance P, substrates of angiotensin-converting enzyme, increase vascular permeability and cause tissue edema in animals. Studies indicate that amino-terminal degradation of these peptides, by aminopeptidase P and dipeptidyl peptidase IV, may be impaired in individuals with ...

Hypertension is considered a major health problem around the world. It’s associated with increasing risk of mortality due to its complication which has great impact on patient’s life quality. Angiotensin Receptor Blocker been widely used manage hypertension, especially if diabetes coexists and patient less tolerable angiotensin-converting enzyme inhibitors. In particular, telmisarta...

Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers have different pharmacologic mechanisms for blocking the effect of the renin-angiotensin-aldosterone system on the cardiovascular system. Pharmacologically, the combination of these drug classes completely blocks the deleterious effect of angiotensin in patients with heart failure. However, clinical trials have not shown...

Background Arterial stiffness and hypertension are strong predictors of cardiovascular disease mortality. Angiotensin-converting enzyme inhibitors (ACEI) angiotensin receptor blockers (ARB) first-line antihypertensive agents in reducing blood pressure arterial stiffness. Objective The objective this study was to compare the effects ACEI ARB preventing target organ damage patients with hypertens...